CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 171 enrolled
Drug / intervention
Donepezil HCLdrug
Likely dose
Donepezil HCL 23 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02097056
NCT02097056Phase 4Completed
CompareCT.gov

Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease

Eisai Korea Inc.·interventional·Posted Mar 26, 2014·Updated Jun 27, 2016

In Brief

A Phase 4 clinical trial evaluating Donepezil HCL for Alzheimer's Disease. Completed, enrolled 171 participants across 13 sites.

Detailed Summary

This is a multi-center, open-label, single-arm, prospective, phase IV trial, evaluating safety and efficacy of donepezil hydrochloride in patients with moderate to severe Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 26, 2014
Enrollment StartFeb 1, 2014
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.3 years ago

Interventions

Donepezil HCLdrug

Donepezil HCl 23 mg once daily, just before bed, for 24 weeks